Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthieu Texier

Showing results (1-10 of 25) with videos related to

Pageof 3
Sort By:
Clinical Lung Cancer|November 23, 2021
PD-1 iNhibitor and chemotherapy with concurrent IRradiation at VAried tumor sites in advanced Non-small cell lung cAncer: the Prospective Randomized Phase 3 NIRVANA-Lung TrialJérôme Doyen, Benjamin Besse, Matthieu Texier, et al.
Computational and Mathematical Methods in Medicine|March 24, 2018
Evaluation of Treatment Effect with Paired Failure Times in a Single-Arm Phase II Trial in OncologyMatthieu Texier, Federico Rotolo, Michel Ducreux, et al.
The Lancet. Oncology|September 30, 2021
Late phase 1 studies: concepts and outcomesJose Carlos Benitez, Arthur Geraud, Matthieu Texier, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 18, 2020
Intratumoral Immunotherapy: From Trial Design to Clinical PracticeStéphane Champiat, Lambros Tselikas, Siham Farhane, et al.
Clinical Lung Cancer|January 26, 2019
Clinical Relevance of EGFR- or KRAS-mutated Subclones in Patients With Advanced Non-small-cell Lung Cancer Receiving Erlotinib in a French Prospective Cohort (IFCT ERMETIC2 Cohort - Part 2)Michèle Beau-Faller, Matthieu Texier, Hélène Blons, et al.
Cancer Treatment Reviews|August 23, 2022
Analysis of the association between prospectively collected immune-related adverse events and survival in patients with solid tumor treated with immune-checkpoint blockers, taking into account immortal-time biasMaria Kfoury, Marie Najean, Ariane Lappara, et al.
Lung Cancer (Amsterdam, Netherlands)|December 26, 2021
Gefitinib plus tremelimumab combination in refractory non-small cell lung cancer patients harbouring EGFR mutations: The GEFTREM phase I trialMariona Riudavets, Marie Naigeon, Matthieu Texier, et al.
JAMA Dermatology|October 27, 2015
Association of Vitiligo With Tumor Response in Patients With Metastatic Melanoma Treated With PembrolizumabCamille Hua, Lise Boussemart, Christine Mateus, et al.
Oncoimmunology|December 22, 2022
Plasma galectins and metabolites in advanced head and neck carcinomas: evidence of distinct immune characteristics linked to hypopharyngeal tumorsBao-Tram Thi Tran, Aurore Gelin, Sylvère Durand, et al.
Nature Reviews. Clinical Oncology|May 5, 2016
Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combinationCeline Boutros, Ahmad Tarhini, Emilie Routier, et al.
Pageof 3

Showing results (1-10 of 25) with videos related to

Sort By:
Pageof 3
Clinical Lung Cancer|November 23, 2021
PD-1 iNhibitor and chemotherapy with concurrent IRradiation at VAried tumor sites in advanced Non-small cell lung cAncer: the Prospective Randomized Phase 3 NIRVANA-Lung TrialJérôme Doyen, Benjamin Besse, Matthieu Texier, et al.
Computational and Mathematical Methods in Medicine|March 24, 2018
Evaluation of Treatment Effect with Paired Failure Times in a Single-Arm Phase II Trial in OncologyMatthieu Texier, Federico Rotolo, Michel Ducreux, et al.
The Lancet. Oncology|September 30, 2021
Late phase 1 studies: concepts and outcomesJose Carlos Benitez, Arthur Geraud, Matthieu Texier, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 18, 2020
Intratumoral Immunotherapy: From Trial Design to Clinical PracticeStéphane Champiat, Lambros Tselikas, Siham Farhane, et al.
Clinical Lung Cancer|January 26, 2019
Clinical Relevance of EGFR- or KRAS-mutated Subclones in Patients With Advanced Non-small-cell Lung Cancer Receiving Erlotinib in a French Prospective Cohort (IFCT ERMETIC2 Cohort - Part 2)Michèle Beau-Faller, Matthieu Texier, Hélène Blons, et al.
Cancer Treatment Reviews|August 23, 2022
Analysis of the association between prospectively collected immune-related adverse events and survival in patients with solid tumor treated with immune-checkpoint blockers, taking into account immortal-time biasMaria Kfoury, Marie Najean, Ariane Lappara, et al.
Lung Cancer (Amsterdam, Netherlands)|December 26, 2021
Gefitinib plus tremelimumab combination in refractory non-small cell lung cancer patients harbouring EGFR mutations: The GEFTREM phase I trialMariona Riudavets, Marie Naigeon, Matthieu Texier, et al.
JAMA Dermatology|October 27, 2015
Association of Vitiligo With Tumor Response in Patients With Metastatic Melanoma Treated With PembrolizumabCamille Hua, Lise Boussemart, Christine Mateus, et al.
Oncoimmunology|December 22, 2022
Plasma galectins and metabolites in advanced head and neck carcinomas: evidence of distinct immune characteristics linked to hypopharyngeal tumorsBao-Tram Thi Tran, Aurore Gelin, Sylvère Durand, et al.
Nature Reviews. Clinical Oncology|May 5, 2016
Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combinationCeline Boutros, Ahmad Tarhini, Emilie Routier, et al.
Pageof 3